Vendis Capital has sealed a €290m sale of Belgian teeth, mouth and skincare products business Sylphar to EQT portfolio business Karo Pharma.
The private equity house bought Sylphar in 2017 from Concordia. The company was formed in 2007 by company CEO Robin List, who remains an investor.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Sylphar’s brands include Nutravita, Alpha Foods, Remescar and iWhite.
Vendis said that since its investment Sylphar had expanded its digital presence, its category of products and its geographic footprint.
Bolt-on acquisitions included Nutravita in 2018 and Alpha Foods in 2020.
EQT bought Sweden’s Karo Pharma two years ago in a $694m deal. The business develops and markets products for pharmacies and other areas of the healthcare sector.
Source: Alt Assets
Can’t stop reading? Read more
Goldman Sachs Alternatives and Blue Owl weigh $3bn private loan for Hg’s OneStream buyout
Goldman Sachs Alternatives and Blue Owl weigh $3bn private loan for Hg’s OneStream buyout Hg is...
PGIM targets private credit secondaries with $1bn deployment plan
PGIM targets private credit secondaries with $1bn deployment plan PGIM is preparing to invest up...
Private capital moves into emerging sports as Athvance launches pan-European platform
Private capital moves into emerging sports as Athvance launches pan-European platform Athvance...